Amlodipine/chlortalidone/telmisartan - Yuhan

Drug Profile

Amlodipine/chlortalidone/telmisartan - Yuhan

Alternative Names: Amlodipine/telmisartan/chlortalidone; Chlortalidone/amlodipine/telmisartan; Chlortalidone/telmisartan/amlodipine; Telmisartan/amlodipine/chlortalidone; Telmisartan/chlortalidone/amlodipine; YH 22162; YH22162 FDC

Latest Information Update: 11 Oct 2018

Price : $50 *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Yuhan
  • Class Antihypertensives; Ischaemic heart disorder therapies; Small molecules
  • Mechanism of Action ACE inhibitors; Angiotensin type 1 receptor antagonists; Calcium channel antagonists; Cytochrome P 450 enzyme system inhibitors; Diuretics; Thiazide-like diuretics
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Essential hypertension

Most Recent Events

  • 11 Oct 2018 Chemical structure information added
  • 10 Sep 2018 Yuhan Corporation plans a phase I pharmacokinetic trial in healthy volunteers (PO) (NCT03662620)
  • 01 Dec 2016 Yuhan Corporation completes a phase III trial in Essential hypertension (Treatment-experienced) in South Korea (PO) (NCT02620163)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top